Xeris Biopharma Holdings
XERS
67 hedge funds and large institutions have $45.8M invested in Xeris Biopharma Holdings in 2020 Q1 according to their latest regulatory filings, with 21 funds opening new positions, 24 increasing their positions, 13 reducing their positions, and 8 closing their positions.
163% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 8
85% more repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 13
24% more funds holding
Funds holding: 54 → 67 (+13)
4% less call options, than puts
Call options by funds: $22K | Put options by funds: $23K
2.8% less ownership
Funds ownership: 65.31% → 62.51% (-2.8%)
64% less capital invested
Capital invested by funds: $128M → $45.8M (-$82.2M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SC
Sessa Capital
New York
|
+$13.9M |
| 2 |
DM
Deerfield Management
New York
|
+$3.66M |
| 3 |
HP
Hound Partners
New York
|
+$2.31M |
| 4 |
AGM
Alpine Global Management
New York
|
+$2.17M |
| 5 |
D.E. Shaw & Co
New York
|
+$2.07M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citigroup
New York
|
-$9.43M |
| 2 |
CLCM
Crawford Lake Capital Management
Lakewood,
New Jersey
|
-$4.16M |
| 3 |
Millennium Management
New York
|
-$1.21M |
| 4 |
ECM
ExodusPoint Capital Management
New York
|
-$331K |
| 5 |
State of Wisconsin Investment Board
Madison,
Wisconsin
|
-$282K |
XERS Hedge Fund Activity: Q1 2020 in Review
67 of the 4,538 institutional investors tracked by Wall St. Rank reported a position in Xeris Biopharma Holdings (XERS) for Q1 2020, worth a combined $45.8M — down 64% from $128M a quarter earlier.
Buyers outnumbered sellers: 21 funds opened new XERS positions and 8 closed out — a net gain of 13 holders — while 24 added to existing stakes and 13 trimmed.
The largest buyer was Sessa Capital, opening a new position worth an estimated $13.9M. The largest seller was Citigroup, cutting an estimated $9.43M.
- 67 institutional investors held Xeris Biopharma Holdings (XERS) as of Q1 2020, up from 54 in Q4 2019.
- Funds reported $45.8M of Xeris Biopharma Holdings stock for Q1 2020, down 64% quarter-over-quarter.
- 21 funds opened new Xeris Biopharma Holdings positions in Q1 2020 and 8 closed out, a net change of +13 holders.
- The largest Xeris Biopharma Holdings buyer in Q1 2020 was Sessa Capital, an estimated $13.9M added.
- The largest Xeris Biopharma Holdings seller in Q1 2020 was Citigroup, an estimated $9.43M sold.
Based on aggregated 13F filings for Q1 2020.